Welcome to our dedicated page for Akoya Biosciences news (Ticker: AKYA), a resource for investors and traders seeking the latest updates and insights on Akoya Biosciences stock.
Akoya Biosciences, Inc. (AKYA) drives innovation in spatial biology through advanced tissue analysis platforms that transform clinical research and diagnostics. This news hub provides investors and researchers with essential updates on the company developments shaping precision medicine.
Access real-time press releases covering AKYA's scientific advancements, financial performance, and strategic partnerships. Our curated collection includes earnings reports, product launch details, and collaborative research initiatives within the life sciences sector.
Key updates feature progress in multiplex imaging technologies, biomarker discovery milestones, and regulatory developments impacting spatial biology applications. Track AKYA's contributions to oncology research, immunology studies, and next-generation diagnostic tools through verified corporate communications.
Bookmark this page for streamlined access to AKYA's official announcements, maintaining informed perspectives on their market position and technological leadership. Combine this resource with Stock Titan's financial analysis tools for comprehensive investment research.
Akoya Biosciences (Nasdaq: AKYA) announced the shipment of its 1,000th instrument, marking a significant milestone and establishing the largest installed base in the spatial biology industry. This achievement highlights the widespread adoption of Akoya's technologies in research laboratories globally and sets the stage for clinical applications. The portfolio features advanced tools such as PhenoCycler®, PhenoImager® Fusion, and PhenoImager HT, enabling precise spatial biomarker identification. CEO Brian McKelligon expressed gratitude to the team for their role in this success and reiterated the commitment to expanding their ecosystem of spatial biology solutions. The 1,000th system was delivered to iHisto, a histopathology lab known for high-quality services and innovative technologies.
Akoya Biosciences, Inc. (Nasdaq: AKYA) has launched the PhenoCode Discovery Panels at the AACR 2023 Annual Meeting in Orlando, aimed at advancing cancer research. These panels facilitate the analysis of tumors and their microenvironment by providing ready-to-use biomarker combinations for immune profiling and tissue architecture assessment. They significantly reduce assay development time, accelerating spatial discovery by up to three times compared to traditional workflows. The company plans to expand its product offerings with more protein biomarker panels throughout 2023 and 2024, along with launching RNA panels in the latter half of 2023. Akoya's innovations aim to streamline workflows for researchers and enhance the capabilities of the PhenoCycler-Fusion platform.
FAQ
What is the current stock price of Akoya Biosciences (AKYA)?
What is the market cap of Akoya Biosciences (AKYA)?
